Table 3.
Antibiotic Susceptibility and Typing of 65 Monoclonal Strains Isolated from 13 Patients
| Strain No. | No. of RAPD patterns | EPIYA Typing | CLA | AMX | LVX | TET | MET |
|---|---|---|---|---|---|---|---|
| G1 | S | S | R | S | R | ||
| G1-1 | 2 | AD | S | S | R | S | R |
| G1-2 | AD | S | S | R | S | R | |
| G1-3 | AD | S | S | R | S | R | |
| G1-4 | ABD | S | S | R | S | S | |
| G1-5 | AD | S | S | R | S | R | |
| G2 | S | S | S | S | R | ||
| G2-1 | 2 | ABD | S | S | S | S | R |
| G2-2 | ABD | S | S | S | S | R | |
| G2-3 | AD | S | S | S | S | S | |
| G2-4 | ABD | S | S | S | S | R | |
| G2-5 | AD | S | S | S | S | S | |
| G3 | R | S | S | S | R | ||
| G3-1 | 2 | ABD | R | S | S | S | R |
| G3-2 | ABD | R | S | S | S | R | |
| G3-3 | ABD | S | S | S | S | S | |
| G3-4 | ABD | S | S | S | S | S | |
| G3-5 | ABD | S | S | S | S | S | |
| G4 | S | S | R | S | S | ||
| G4-1 | 2 | AD | S | S | S | S | S |
| G4-2 | ABD | S | S | R | S | S | |
| G4-3 | AD | S | S | S | S | S | |
| G4-4 | AD | S | S | S | S | S | |
| G4-5 | AD | S | S | S | S | S | |
| G5 | S | S | S | S | S | ||
| G5-1 | 2 | ABD | S | S | S | S | S |
| G5-2 | AD | S | S | S | S | S | |
| G5-3 | ABD | S | S | S | S | S | |
| G5-4 | ABD | S | S | S | S | S | |
| G5-5 | ABD | S | S | S | S | S | |
| G6 | S | S | S | S | R | ||
| G6-1 | 1 | ABC | S | S | S | S | R |
| G6-2 | ABC | S | S | S | S | R | |
| G6-3 | ABC | S | S | S | S | R | |
| G6-4 | ABC | S | S | S | S | R | |
| G6-5 | ABC | S | S | S | S | R | |
| G7 | S | S | R | S | S | ||
| G7-1 | 3 | AD | S | S | R | S | S |
| G7-2 | ABDD | S | S | R | S | S | |
| G7-3 | ABD | S | S | R | S | S | |
| G7-4 | ABD | S | S | R | S | S | |
| G7-5 | ABD | S | S | R | S | S | |
| G8 | R | R | R | R | R | ||
| G8-1 | 3 | ABD | S | R | R | R | R |
| G8-2 | ABD | R | S | R | R | R | |
| G8-3 | ABD | S | R | R | R | R | |
| G8-4 | ABD | R | S | R | R | R | |
| G8-5 | AB | R | R | S | R | R | |
| G9 | R | S | S | S | S | ||
| G9-1 | 1 | ABD | R | S | S | S | S |
| G9-2 | ABD | R | S | S | S | S | |
| G9-3 | ABD | R | S | S | S | S | |
| G9-4 | ABD | R | S | S | S | S | |
| G9-5 | ABD | R | S | S | S | S | |
| G10 | R | S | R | S | R | ||
| G10-1 | 3 | ABD | S | S | R | S | R |
| G10-2 | ABD | R | S | R | S | R | |
| G10-3 | ABD | R | S | R | S | R | |
| G10-4 | ABD | R | S | R | S | R | |
| G10-5 | BD | S | S | S | S | R | |
| G11 | S | S | S | S | S | ||
| G11-1 | 2 | ABC | S | S | S | S | S |
| G11-2 | ABC | S | S | S | S | S | |
| G11-3 | AC | S | S | S | S | S | |
| G11-4 | AC | S | S | S | S | S | |
| G11-5 | AC | S | S | S | S | S | |
| G12 | S | S | S | S | R | ||
| G12-1 | 1 | ABD | S | S | S | S | R |
| G12-2 | ABD | S | S | S | S | R | |
| G12-3 | ABD | S | S | S | S | R | |
| G12-4 | ABD | S | S | S | S | R | |
| G12-5 | ABD | S | S | S | S | R | |
| G13 | R | R | R | S | R | ||
| G13-1 | 3 | AD | R | S | S | S | R |
| G13-2 | ABC | R | R | R | S | R | |
| G13-3 | ABC | R | R | R | S | R | |
| G13-4 | ABD | S | S | R | S | R | |
| G13-5 | ABD | S | S | R | S | R |
Notes: CagA are characterized by the unique 5-amino-acid sequence (Glu-Pro-Ile-Tyr-Ala), termed the EPIYA motif, which is present in variable numbers in the C-terminal CagA region. Based on the flanking amino acid sequences of variable EPIYA-repeat region, EPIYA can be further classified into four motifs: EPIYA-A, -B, -C, and –D, then according to the composition of the EPIYA-A, -B, -C, and D motifs, H. pylori can be classified into different cagA genotypes, such as cagA-AB, -ABC, -ABD or-BD.
Abbreviations: AMX, amoxicillin; CLA, clarithromycin; LVX, levofloxacin; MET, metronidazole; TET, tetracycline; R, resistant; S, susceptible; RAPD, random amplified polymorphic DNA.